Skip to main content
. 2018 Feb 5;11:736. doi: 10.3389/fnins.2017.00736

Figure 6.

Figure 6

TGF-β treatment regulates TIMP-1 expression. C116- and HD-NSCs were treated with 10 ng/mL TGF-β for 24 h. (A) Immunoblot analysis demonstrates that both corrected C116- and HD-NSCs express the TGF-β receptor at equal levels, and that exogenous TGF-β administration does not modulate expression of its cognate receptor (ANOVA with Tukey's multiple comparison test). Western blot analysis reveals that TGF-β treatment resulted in increased expression of TIMP-1 in HD-NSCs (B), but not in C116-NSCs. No changes are observed in the expression levels of TIMP-2 (C) and MMP-3/10 (D) in response to TGF-β, however, a very modest increase is observed in MMP-14 expression in HD-NSCs (E) (*p < 0.05; ****p < 0.0001; t-test). Error bars represent SD.